Quantcast

Latest Intravenous immunoglobulin Stories

2010-11-18 15:27:00

ANAHEIM, Calif., Nov. 18, 2010 /PRNewswire/ -- Crescent Healthcare today announced a planned expansion of their east coast operations in 2011. They signed a lease to open an infusion pharmacy in Totowa, New Jersey, central to providing immune globulin therapies and services to current patients in Massachusetts, Maryland, New York, New Jersey, Pennsylvania, Connecticut, Delaware, District of Columbia, and Rhode Island. In addition to supporting current business in the northeast, the new...

2010-10-14 09:22:00

RESEARCH TRIANGLE PARK , N.C., Oct. 14 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics (Nasdaq: TLCR) announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex®-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI). The newly approved Gamunex-C provides both the intravenous route of administration and a new subcutaneous route of...

2010-10-07 00:00:00

ISTANBUL, Oct. 7 /PRNewswire/ -- Vivaglobin® (subcutaneous immunoglobulin [IgG]) (SCIg) is an effective and safe initial therapy for treatment-naive patients with primary immunodeficiency (PI) and may offer an attractive alternative to intravenous IgG (IVIg) therapy in the newly diagnosed, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies. The study found that IgG replacement therapy initiated with Vivaglobin in patients...

2010-10-07 00:00:00

ISTANBUL, Oct. 7 /PRNewswire/ -- Privigen®, the first and only 10% liquid intravenous immunoglobulin (IVIg) therapy stabilized with proline, is effective and well tolerated in patients with several primary and secondary immunodeficiencies, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies. Results also demonstrate that Privigen offers significant protection against infection. In a separate observational study, patients...

2010-10-07 00:00:00

ISTANBUL, Oct. 7 /PRNewswire/ -- Hizentra® (IgPro20) provides primary immunodeficiency (PI) patients with a safe and effective alternative to other immunoglobulin therapies when given in equivalent doses, according to Phase III pivotal trial data presented today at the XIVth Meeting of the European Society for Immunodeficiencies (ESID). Hizentra, the first and only 20 percent SCIg developed for subcutaneous (i.e., under the skin) administration, can be stored at room...

2010-08-03 14:46:17

Scientists report that viral infection of the heart is a predictor of heart transplant failure in young children and adolescents, although it can be detected by screening for viral genes and treated to improve organ survival. Published online Aug. 2 (Aug. 10 issue) in the Journal of the American College of Cardiology, the study suggests a therapeutic strategy for overcoming one of the major challenges facing young heart transplant recipients "“ that of organ failure caused by viral...

2010-06-29 09:48:00

PLYMOUTH, Minn., June 29 /PRNewswire/ -- Midwest Infusion Center expanded from its previous space at West Health by opening a new infusion center at the City Center Professional Building in Plymouth for patients receiving infusion therapy. Midwest Infusion Center is a unique treatment center designed for patients to receive complex therapies in a safe, comfortable and non-clinical setting. The team, staffed with physicians and registered nurses who are experts in infusion therapy, works...

2010-06-02 14:30:00

BARCELONA, Spain, June 2 /PRNewswire/ -- Grifols, SA, a global healthcare company focused on clinical applications of human plasma proteins, announced at its annual meeting with investors and analysts, that it will initiate a new clinical investigation of Alzheimer's Disease in January 2011 with an anticipated enrollment of over 300 patients. The new clinical investigation involves a combined treatment of therapeutic plasmapheresis and the administration of human albumin and...

2010-04-19 07:31:00

KING OF PRUSSIA, Pa., April 19 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to extend the shelf life for Privigen®, Immune Globulin Intravenous (Human), 10% Liquid, from 24 to 36 months. The approval makes Privigen the first liquid intravenous immunoglobulin (IVIg) in the U.S. that can be stored at room temperature throughout its entire 36-month shelf life....

2010-04-12 10:07:00

RESEARCH TRIANGLE PARK, N.C., April 12 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics, Inc., today announced results of a new survey showing that Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) is the preferred immune globulin intravenous (IGIV) among neurologists who indicated a brand preference. In the survey, conducted online by Harris Interactive® on behalf of Talecris, neurologists selected Gamunex over...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'